Renaissance Technologies LLC increased its holdings in Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) by 1,494.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,453,244 shares of the company’s stock after acquiring an additional 1,362,100 shares during the quarter. Renaissance Technologies LLC’s holdings in Elanco Animal Health were worth $17,759,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Quadrant Capital Group LLC increased its holdings in shares of Elanco Animal Health by 281.7% in the 4th quarter. Quadrant Capital Group LLC now owns 2,706 shares of the company’s stock valued at $33,000 after acquiring an additional 1,997 shares during the period. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Elanco Animal Health by 257.2% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock valued at $35,000 after acquiring an additional 2,055 shares during the period. Signaturefd LLC increased its holdings in shares of Elanco Animal Health by 97.4% in the 3rd quarter. Signaturefd LLC now owns 3,306 shares of the company’s stock valued at $41,000 after acquiring an additional 1,631 shares during the period. Eisler Capital UK Ltd. acquired a new position in shares of Elanco Animal Health in the 3rd quarter valued at $46,000. Finally, UMB Bank has increased its holdings in shares of Elanco Animal Health by 26.9% in the 4th quarter. UMB Bank now owns 3,747 shares of the company’s stock valued at $46,000 after acquiring an additional 795 shares during the period.
Elanco Animal Health Stock Performance
NYSE:ELAN opened at $9.06 on Friday. The company has a quick ratio of 1.24, a current ratio of 2.25 and a debt-to-equity ratio of 0.75. Elanco Animal Health Incorporated has a fifty-two week low of $7.88 and a fifty-two week high of $23.32. The stock has a market cap of $4.46 billion, a PE ratio of -226.44, a price-to-earnings-growth ratio of 6.60 and a beta of 0.92. The firm’s fifty day simple moving average is $9.06 and its 200-day simple moving average is $10.96.
Elanco Animal Health (NYSE:ELAN – Get Rating) last posted its quarterly earnings results on Tuesday, May 9th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.29 by $0.16. Elanco Animal Health has a negative net margin of 0.49% and a positive return on equity of 8.21%. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same period in the prior year, the company posted $0.36 EPS. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. Analysts expect that Elanco Animal Health Incorporated will post 0.8 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
ELAN has been the topic of several recent research reports. Piper Sandler dropped their price objective on shares of Elanco Animal Health from $15.00 to $12.00 in a research note on Thursday, March 2nd. Barclays raised shares of Elanco Animal Health from an “equal weight” rating to an “overweight” rating and set a $14.00 price objective on the stock in a research note on Thursday, April 20th. One equity research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health currently has a consensus rating of “Hold” and an average target price of $16.50.
About Elanco Animal Health
(Get Rating)
Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.
Further Reading
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating).
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.
